Gina Mauro

Alecensa cut the risk of death by 22% versus Xalkori, with median overall survival reaching 81.1 months versus 54.2 months in advanced ALK-positive lung cancer.

Here is a basic guide to what you need to know about stage 2 papillary thyroid cancer.

Get the facts on stage 1 multiple myeloma, including why your doctor may recommend active surveillance and what the latest treatment options are.

Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T cell therapy is changing treatment decisions.

In PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma buparlisib and paclitaxel was not associated with a survival improvement.

Sacituzumab tirumotecan cut risk of progression or death by 51% versus chemotherapy in EGFR-mutated NSCLC after tyrosine kinase inhibitor resistance.

In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.

Understand why early detection gives you the best chance, explore your surgery or radiation options, and plan for survivorship with oral cavity cancer.

This stage 1 prostate cancer guide explains diagnosis, Gleason scores, and the choice between surgery, radiation and active surveillance.

Kelly Dyckman discusses the mind-body connection during cancer care, offering tools for coping with diagnosis and intimacy struggles.

This in-depth guide offers a clear look at papillary thyroid cancer, from initial diagnosis and treatment options to long-term prognosis and living well after treatment.

Nancee Pronsati discusses a new patient-authored guide for managing ALK-directed treatment side effects in lung cancer and improving quality of life.

Diagnosed with multiple myeloma? Our guide explains each stage and treatment, helping you engage confidently with your care team.

This guide for newly diagnosed patients provides key information to help you understand your options and have informed conversations with your oncologist.

This comprehensive guide provides essential information to help patients and their families navigate their prostate cancer journey.

Learn about diagnosis, explore your thyroid cancer treatment options and find practical advice for managing side effects and living well after treatment.

Multiple myeloma is a chronic blood cancer affecting plasma cells, but with today’s treatments many patients can manage symptoms and live fulfilling lives.

Support and research for epithelioid hemangioendothelioma are growing, with the EHE Foundation helping connect patients to expert care and resources.

Treatment options for patients with epithelioid hemangioendothelioma vary dependent on disease status, but more therapies are under investigation.

Dr. Michael Wagner covers the basics of epithelioid hemangioendothelioma, a rare vascular cancer, spanning symptoms, diagnosis, treatment options and more.

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses.

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

PD-L1 expression was found to predict better outcomes with Opdivo and Yervoy in patients with ccRCC, while high KIM-1 levels were linked to worse outcomes.

Findings from the CheckMate 067 of patients with advanced melanoma include the longest follow-up of a checkpoint inhibitor in any tumor type.

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among patients with high-risk endometrial cancer.

An analysis of more than 500 patients with advanced kidney cancer treated with Welireg broke down the rates of moderate to severe side effects.

Some patients with stage 3 non-small cell lung cancer saw benefits from Opdivo plus chemotherapy followed by surgery then Opdivo, researchers found.

Zanidatamab continued to lead to responses and improved overall survival in pretreated HER2-positive biliary tract cancer.

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.